Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Dow
McKesson
Colorcon
Harvard Business School

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Remimazolam

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Remimazolam: Patents, clinical trial progress, indications

Remimazolam is an investigational drug.

There have been 15 clinical trials for Remimazolam. The most recent clinical trial was a Phase 3 trial, which was initiated on June 28th 2018.

The most common disease conditions in clinical trials are Substance-Related Disorders and [disabled in preview]. The leading clinical trial sponsors are Paion UK Ltd., Jiangsu HengRui Medicine Co., Ltd., and PRA Health Sciences.

There are twenty US patents protecting this investigational drug and one hundred and eighteen international patents.

Recent Clinical Trials for Remimazolam
TitleSponsorPhase
A Clinical Study of Remimazolam Tosilate Compared to Propofol for General Anesthesia During Elective SurgeryJiangsu HengRui Medicine Co., Ltd.Phase 3
Efficacy and Safety of Remimazolam (CNS7056) Compared to Propofol for Intravenous Anesthesia During Elective SurgeryCreative Clinical Research GmbHPhase 3
Efficacy and Safety of Remimazolam (CNS7056) Compared to Propofol for Intravenous Anesthesia During Elective SurgeryORION Clinical ServicesPhase 3

See all Remimazolam clinical trials

Clinical Trial Summary for Remimazolam

Top disease conditions for Remimazolam
Top clinical trial sponsors for Remimazolam

See all Remimazolam clinical trials

US Patents for Remimazolam

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Remimazolam   Start Trial Process for preparing 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4H-imidazo[1,2-A][1,4]benzodiaze- pine-4-yl]propionic acid methyl ester or the benzene sulfonate salt thereof, and compounds useful in that process PAION UK LIMITED (Cambridge, Cambridgeshire, GB)   Start Trial
Remimazolam   Start Trial Dosing regimen for sedation with CNS 7056 (remimazolam) PAION UK LTD. (Histon Cambridge, GB)   Start Trial
Remimazolam   Start Trial Dosing regimen for sedation with CNS 7056 (Remimazolam) PAION UK LTD. (Histon, Cambridge, unknown)   Start Trial
Remimazolam   Start Trial Short-acting benzodiazepines CeNeS Limited (Cambridge, GB)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Remimazolam

Drugname Country Document Number Estimated Expiration Related US Patent
Remimazolam Australia 2010294873 2029-09-18   Start Trial
Remimazolam Canada 2774018 2029-09-18   Start Trial
Remimazolam China 102753525 2029-09-18   Start Trial
Remimazolam Denmark 2477967 2029-09-18   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
AstraZeneca
Colorcon
McKinsey
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.